The Asia Pacific Hematology market size is estimated to grow at a high CAGR from 2022 to 2027.
The increasing incidence of blood disorders is one of the primary factors boosting the hematology market in the Asia Pacific region. Blood disorders are becoming heath issue worldwide and are also increasing the mortality rates of many countries. Furthermore, with the increase in population, blood disorders such as anemia, blood cancer, hemorrhagic conditions, and blood infections affect many people worldwide. As the Asia region is highly populated, blood disorders are being affected most and accelerating the market's growth in APAC.
Blood donation camps are increasing rapidly and increasing awareness in the people about the advantages of blood donations to society. This is increasing the demand for the Haematology market. As the elderly population is rising, growth in chronic diseases is rising, boosting the development of the market. New opportunities are being introduced with advancements in the technologies such as care testing devices. The government is also investing in the hematology market, driving the increase in the APAC Haematology Market. New low-cost diagnosis is introduced in this market that people are interested in and is expected to develop the market.
However, a lack of awareness about blood donation in rural regions is hampering the market's growth. The major drawback of this market is the cost of installing is very high. The manufacturing and maintenance of the equipment cost are also very high. These factors are expected to be hampering the growth of the market. In addition, strict government rules in launching the new product and product recalls are further estimated to restrain the development of the market in the forecast period.
This research report on the Asia Pacific Hematology Market has been segmented and sub-segmented into the following categories:
The key factors such as increasing investments by the government into the R&D department, increase in the use of automated hematology instruments in many laboratories, increase in the fast testing of hematology are rapidly accelerating the hematology market in the APAC and expected to position the APAC as the fastest-growing regional markets globally.
In the Asia Pacific region, China had the largest share in the APAC Hematology Market in 2020. The main driver for this market in China's increasing elderly population is growing chronic diseases that boost the growth of the market. Hematological testing became very important with the recent outbreak of COVID-19. As a result, the demand for hematology products has increased in various regions, which increased the need for the APAC Haematology Market.
Followed by China, Japan had the highest share in APAC Haematology Market. The new advancements in hematology analyzers with POC testing, rapid testing kits, new automation technologies are increasing the demand for the market. Globally in the hematology analyzers and reagents market, Japan is leading. Sysmex company is said to be leading in the supply of instruments and reagents in diagnostics. New research investments and new product launches are prominent in the future growth of the APAC Hematology market. These are the main factors behind the future development of the APAC Hematology Market.
KEY MARKET PLAYERS:
Companies playing a leading role in the Asia Pacific Hematology Market profiled in this report are Siemens AG Healthcare, Johnson & Johnson, Beckman Coulter, Inc., Abbott Laboratories, Thermo Fisher Scientific, Roche, HORIBA Ltd., Sysmex Corporation, Bio-Rad Laboratories Inc., Boule Diagnostics AB, Mindray Medical International Limited.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org